Date: April 16, 2025 | Location: Washington, D.C. | Time: 8am to 4pm (ET)
Using Atrial Fibrillation Burden as a Regulatory Outcome
Contribute your thoughts along with the FDA, industry, and academic experts in a focused discussion to help define the best current thinking on the use of atrial fibrillation burden as a regulatory endpoint.
Specific topics to be discussed are:
- Can AFib burden be used in its current form to achieve clinical and regulatory goals?
- Can AFib burden serve as a surrogate for heart failure, stroke, hospitalization, quality of life, or cognitive decline?
- Should AFib burden be measured continuously or intermittently?
- Does the measurement of AFib burden require a new statistical approach?
Findings will be published in a multi-stakeholder-authored peer-reviewed manuscript.
To be part of this important discussion, please join us on April 16th, 2025, in Washington, DC. Spaces are limited, so register as soon as possible.
SHARE THIS EVENT